• Jeffrey B Washam, Babatunde Yerokun, Chetan B Patel, Ian J Welsby, Carmelo A Milano, and Adam D DeVore.
• Duke Heart Center, Duke University Medical Center, DUMC Box 3943, Durham, NC, 27710, USA. jeff.washam@duke.edu.
• J. Thromb. Thrombolysis. 2018 Aug 1; 46 (2): 131-133.

AbstractBleeding frequently occurs in patients undergoing placement of a left ventricular assist device (LVAD). Clinical factors that have been identified as contributing to peri-procedural bleeding include LVAD implantation after an acute myocardial infarction and preoperative use of antiplatelet agents. In this report, we describe the use of cangrelor for preoperative antiplatelet bridging to LVAD in five post myocardial infarction patients with cardiogenic shock that had recently undergone percutaneous coronary intervention. During the cangrelor bridging period, no cases of thrombotic or major bleeding events occurred. During the first week following LVAD implantation, two patients experienced a major bleeding (each case required chest exploration for suspected hemorrhage). To our knowledge, this is the first series describing cangrelor use for antiplatelet bridging in patients undergoing LVAD implantation. While this series suggest cangrelor could possibly be a safe and effective antiplatelet bridging strategy, further research is needed to identify the optimal antithrombotic strategy in cardiogenic shock patients undergoing LVAD implantation who have recently undergoing percutaneous coronary intervention.

22 keywords...

hide…